Skip to main content
NewslettersWatchlist

Sangamo Therapeutics(SGMO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.5200
Day High0.5598
Open:0.5200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Business Wire
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
Business Wire
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Business Wire
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
MarketBeat
There's a Lot of Upside For Emerging Gene-Editing Companies
Business Wire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
Motley Fool
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Business Wire
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
Business Wire
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated ฮฑ-Gal A Enzyme Activity in Nine Patients
Business Wire
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated ฮฑ-gal A Enzyme Activity in Five Longest Treated Patients
Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Business Wire
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
Business Wire
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
Business Wire
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Business Wire
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Business Wire
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
Business Wire
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Business Wire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
Business Wire
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated ฮฑ-Gal A Enzyme Activity in Patients With Fabry Disease
Business Wire
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
Business Wire
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
Business Wire
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Business Wire
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Business Wire
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
Business Wire
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated ฮฑ-Gal A Enzyme Activity in Patients With Fabry Disease
Business Wire
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast

Profile

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.